Sidney Kimmel Comprehensive Cancer Center

The blockade of immune checkpoints in cancer immunotherapy

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival...

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (...

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab tha...

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...

A framework for advancing our understanding of cancer-associated fibroblasts

High Frequency of Mutations of the <i>PIK3CA</i> Gene in Human Cancers

3,1232,680MetricsTotal Downloads3,123Last 6 Months470Last 12 Months1,013Total Citations2,680Last 6 Months51Last 12 Months112View all metrics

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Purpose Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and ...

Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention

A substantial fraction of mutations in human cancer are attributable to random errors occurring during DNA replication.